TD Private Client Wealth LLC Has $1.84 Million Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

TD Private Client Wealth LLC decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 23.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 9,342 shares of the medical research company's stock after selling 2,883 shares during the quarter. TD Private Client Wealth LLC's holdings in Charles River Laboratories International were worth $1,840,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Boston Trust Walden Corp raised its holdings in shares of Charles River Laboratories International by 2.8% during the second quarter. Boston Trust Walden Corp now owns 200,314 shares of the medical research company's stock valued at $41,381,000 after acquiring an additional 5,375 shares during the period. State Street Corp grew its position in Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock worth $419,601,000 after purchasing an additional 41,421 shares in the last quarter. Quest Partners LLC raised its stake in Charles River Laboratories International by 135,175.0% during the 2nd quarter. Quest Partners LLC now owns 5,411 shares of the medical research company's stock valued at $1,118,000 after purchasing an additional 5,407 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Charles River Laboratories International by 3.4% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company's stock valued at $22,060,000 after purchasing an additional 3,714 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Charles River Laboratories International by 6.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company's stock worth $101,483,000 after buying an additional 32,311 shares during the period. Institutional investors own 98.91% of the company's stock.

Insiders Place Their Bets

In other news, Director Richard F. Wallman sold 6,621 shares of the firm's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the sale, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Down 2.0 %

Shares of CRL traded down $3.82 during trading hours on Friday, hitting $190.45. 547,680 shares of the company were exchanged, compared to its average volume of 616,658. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The company has a market cap of $9.74 billion, a PE ratio of 23.84, a PEG ratio of 5.00 and a beta of 1.38. The firm's 50 day moving average is $194.35 and its 200-day moving average is $203.10. Charles River Laboratories International, Inc. has a 52 week low of $176.48 and a 52 week high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same quarter last year, the company posted $2.72 earnings per share. The company's revenue for the quarter was down 1.6% compared to the same quarter last year. On average, equities research analysts forecast that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on CRL. UBS Group increased their price objective on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Evercore ISI raised their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an "in-line" rating in a report on Thursday, November 7th. TD Cowen boosted their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research report on Monday, November 11th. Bank of America cut their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research report on Friday. Finally, Redburn Atlantic began coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They set a "sell" rating and a $151.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International currently has an average rating of "Hold" and a consensus target price of $214.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).